Focused On-demand Library for Mediator of RNA polymerase II transcription subunit 12-like protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q86YW9

UPID:

MD12L_HUMAN

Alternative names:

Mediator complex subunit 12-like protein; Thyroid hormone receptor-associated-like protein; Trinucleotide repeat-containing gene 11 protein-like

Alternative UPACC:

Q86YW9; Q96PC7; Q96PC8; Q9H9M5; Q9HCD7; Q9UI69

Background:

The Mediator of RNA polymerase II transcription subunit 12-like protein, also known as Mediator complex subunit 12-like protein, plays a pivotal role in the transcriptional regulation of genes. It acts as a bridge, facilitating the transfer of information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. This protein is essential for the assembly of a functional preinitiation complex, which is crucial for the transcription of nearly all RNA polymerase II-dependent genes.

Therapeutic significance:

Linked to Nizon-Isidor syndrome, a neurodevelopmental disorder with symptoms ranging from intellectual disability to behavioral abnormalities, the Mediator of RNA polymerase II transcription subunit 12-like protein's study could lead to novel therapeutic strategies. Understanding its role in gene transcription regulation offers a promising avenue for addressing the underlying genetic causes of this syndrome.